Welcome to our dedicated page for InspireMD SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InspireMD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InspireMD's regulatory disclosures and financial reporting.
InspireMD, Inc. filed an 8-K announcing it furnished a press release with financial and operating results and recent highlights for the three and nine months ended September 30, 2025. The materials were provided on November 4, 2025 and relate to performance through Q3 2025.
The company also furnished an updated investor presentation dated November 2025. Both items were submitted under Items 2.02 and 7.01 and are designated as “furnished,” not “filed,” under the Exchange Act. Exhibits include the press release (99.1), the presentation (99.2), and the cover page inline XBRL file (104).
Director Gary S. Roubin received 48,000 restricted shares of InspireMD common stock on 10/07/2025. The shares were issued at $0 and will vest on 10/07/2026 subject to continued service, increasing his total beneficial ownership to 656,425 shares. The grant is recorded as restricted stock and the transaction was reported on a Form 4 filed by a single reporting person.
InspireMD director Danny L. Dearen reported beneficial ownership of 58,017 shares of the company's common stock, comprised of 2,000 shares purchased on the open market and 56,017 restricted shares that are stated to vest on September 16, 2026 subject to continued service, with a provision that unvested shares will fully vest if he is not reelected or not nominated for reelection at the 2026 annual meeting. The filing also shows options to purchase 28,206 shares of common stock at an exercise price of $2.41. The option entry lists an exercisable date of 09/16/2035 in the table while the explanation states the options vest on 09/16/2026, creating an inconsistency in exercisability timing in the filing.
Thomas J. Kester reported transactions in InspireMD, Inc. (NSPR) on a Form 4 filed 09/17/2025. The filing shows a grant of 37,815 shares of common stock on 09/15/2025 for services rendered as a director, increasing his beneficial ownership to 458,573 shares. The report also discloses an option grant of 19,041 options with a $2.38 exercise price, exercisable 09/15/2025 and expiring 09/15/2027, covering 19,041 underlying common shares. The explanatory note states these equity awards were granted in 2025 prior to Mr. Kester's resignation as a director, effective 09/16/2025. The form is signed 09/17/2025.
InspireMD, Inc. reported a planned board transition, with longtime director Thomas J. Kester resigning effective September 16, 2025, and affirming that his departure was not due to any disagreement over company operations or policies.
The board appointed Danny Lee Dearen Jr. as a Class III director, chair of the audit committee, and member of the compensation committee, with a term through the 2026 annual meeting. He received equity awards valued at about $180,000, split 75% in restricted stock and 25% in options, vesting after one year or sooner if he is not renominated or reelected in 2026. In recognition of Kester’s service, the compensation committee accelerated his unvested equity, extended his option terms by two years, approved four additional quarters of director and committee fees, and granted additional stock and options totaling about $120,000.
InspireMD, Inc. updated its prior disclosure about board member Raymond W. Cohen. The company’s board has now appointed Mr. Cohen to serve on both the Audit Committee and the Compensation Committee, in addition to his existing role as a Class 3 director with a term running through the 2026 annual meeting.
Rosalind Advisors, Inc. and affiliated funds disclose aggregate beneficial ownership of 10,987,104 shares of InspireMD, Inc., equal to 9.9% of the 41,720,662 shares used for the calculation. The reported position combines 3,905,743 currently outstanding common shares and 7,081,361 shares issuable upon exercise of warrants as reflected on the cover pages.
The filing notes that the warrants include blocker provisions preventing exercise to the extent such exercise would raise beneficial ownership above 9.99%, so the actual exercisable shares are limited. The Schedule 13G/A is certified and signed by the reporting persons on 08/11/2025.
Rosalind Advisors and affiliated funds report shared beneficial ownership in InspireMD (NSPR), including common shares and warrants that together total 10,987,104 securities representing 9.4% of the class as stated on the cover page. The holding is shown as 3,905,743 common shares plus 7,081,361 shares issuable on warrants for the Advisor group, while Rosalind Master Fund L.P. reports 3,508,336 common and 5,977,361 warrant-issuable shares, and Rosalind Opportunities Fund I L.P. reports 397,407 common and 1,104,000 warrant-issuable shares. The filing notes that blocker provisions limit exercise of some warrants, so the actual exercisable ownership is lower than the raw totals. The Advisor and certain principals disclaim beneficial ownership of shares held by advised funds.
Rosalind Advisors, related funds and principals report material holdings in InspireMD (NSPR). The filing shows aggregate beneficial positions reported as 10,987,104 shares for several Reporting Persons, which the filing presents as approximately 9.4% of the class based on the S-3 share count and other per-entity percentages (Rosalind Master Fund L.P. 9.485,697 shares / 8.4%; Rosalind Opportunities Fund I L.P. 1,501,407 shares / 0.9%).
The reported totals include both currently outstanding common shares and shares issuable upon exercise of warrants (for example, Rosalind Advisors reports 3,905,743 common shares plus 7,081,361 shares issuable on warrants). The filing also discloses blocker provisions that prevent exercise of warrants to the extent doing so would push beneficial ownership above 9.99%, so the practical exercisable interest is lower than the raw issuable amount. The filing includes a certification that the holdings are held in the ordinary course of business and not for the purpose of changing control.